$HELP News
Last published 1w ago
- 1w agoHELPHelus Pharma to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswireNEW YORK and TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving
- 2w agoHELPHelus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of DevelopmentGlobeNewswireCo-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately
- 3w agoHELPHelus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026GlobeNewswireTopline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder ("MDD") on track for Q4 20261,2 HLP004 Program progressing with
- 3w agoHELPHelus Pharma Investor Presentation - HELUS PHARMA INCEarnings Call TranscriptsHealing is not a moment. It's a process. It starts with a question, a hypothesis, a willingness to look deeper, to follow the data, to test, analyze, and learn, to pursue novel solutions with the discipline of science an
- 3w agoHELPHelus Pharma Appoints Dr. Suresh Durgam to Board of DirectorsGlobeNewswireThis news release constitutes a "designated news release" for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as
- 1mo agoHELPHelus Pharma to Host Investor Presentation on October 21, 2026GlobeNewswireNEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds
- 1mo agoHELPTD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - CYBIN INCEarnings Call TranscriptsGood morning, everyone. Welcome to the T.D. Cowan 6th Annual Novel Mechanisms Neuropsychiatry Virtual Summit. I'm covering analyst Ritu Baral, and I will be hosting today with my colleague, Managing Director Joe Thome, a
- 1mo agoHELPTD COWEN 6TH ANNUAL NOVEL MECHANISMS IN NEUROPSYCHIATRY SUMMIT - CYBIN INCEarnings Call TranscriptsGood morning, everyone. Welcome to the T.D. Cowan 6th Annual Novel Mechanisms Neuropsychiatry Virtual Summit. I'm covering analyst Ritu Baral, and I will be hosting today with my colleague, Managing Director Joe Thome, a
- 1mo agoHELPHelus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry SummitGlobeNewswireNEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
- 1mo agoHELPHelus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026GlobeNewswirePoster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatmentfor major depressive disorder ("MDD") NEW YORK and
- 1mo agoHELPHelus Pharma - 1775809 - CYBIN INCEarnings Call TranscriptsWell, good morning, everyone. Thank you for joining me today for this fireside chat with the CEO of Helus Pharma, Michael Holstead. Let me quickly read the Morgan Stanley Research Disclosure. So, for important disclosure
- 1mo agoHELPHelus Pharma - Morgan Stanley 24th Annual Global Healthcare Conference - CYBIN INCEarnings Call TranscriptsWell, good morning, everyone. Thank you for joining me today for this fireside chat with the CEO of Helus Pharma, Michael Holstead. Let me quickly read the Morgan Stanley Research Disclosure. So, for important disclosure
- 2mo agoHELPHelus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkGlobeNewswireNEW YORK and TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
- 2mo agoHELPHelus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New YorkGlobeNewswireNEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
- 2mo agoHELPHelus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New YorkGlobeNewswireNEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
- 2mo agoHELPHelus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory BoardGlobeNewswireFormer Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals and
- 2mo agoHELPHelus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business HighlightsGlobeNewswire- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3
- 3mo agoHELPCG 46TH ANNUAL GROWTH CONFERENCE - CYBIN INCEarnings Call TranscriptsGood afternoon, everyone. I'm Samanth Kulkarni, a senior biotechnology analyst with Canaccord Genuity, and it's my pleasure to have Helus with us today. The ticker is HELP, and they really are in the business of helping
- 3mo agoHELPHelus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in BostonGlobeNewswireNEW YORK and TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds
- 3mo agoHELPDFTXCMPSJNJ+1A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ReadoutGlobeNewswireNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it
- 3mo agoHELPHelus Pharma Appoints Michael Halstead as Chief Executive OfficerGlobeNewswireFormer President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of
- 3mo agoHELPHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of SchedulePR NewswireHelus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma") a clinical stage pharmaceutical company committed to helping minds heal ...
- 3mo agoHELPCMPSGHRSDFTX+1A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps WideningPR NewswireUSA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. ...
- 3mo agoHELPLLYATAICMPS+1Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation AcceleratesPR NewswireMarket News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in ...
- 3mo agoHELPHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of ScheduleGlobeNewswireEnrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH
- 3mo agoLLYDFTXCMPSHELP+4The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBCEli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- 3mo agoHELPLLYATAICMPS+2Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimePR NewswireFor half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY)...
- 4mo agoHELPDFTXCMPSGHRS+1Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityGlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on
- 4mo agoHELPHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsGlobeNewswire- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New
- 4mo agoHELPCMPSDFTXGHRSA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearPR NewswireUSA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data...
- 4mo agoHELPHelus Pharma™ Announces Closing of US$50 Million Underwritten OfferingGlobeNewswireNEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds
- 4mo agoHELPHelus Pharma™ Announces US$50 Million Underwritten OfferingGlobeNewswireNEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical stage pharmaceutical company committed to helping minds
- 4mo agoHELPHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment ProgressGlobeNewswire- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated
- 5mo agoHELPHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives ConferenceGlobeNewswireNEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists
- 5mo agoHELPJeffries Global Healthcare Conference in New York - CYBIN INCEarnings Call TranscriptsAll right, we're going to get started with our next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and thanks for tuning in. It's my pleasure to have Eric Tso, Interim CEO of Helus, joining me. Welcome, E
- 5mo agoHELPHelus Pharma to Participate in the Jefferies Global Healthcare Conference in New YorkGlobeNewswireEric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage
- 6mo agoHELPCORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthGlobeNewswireNEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP), please note references to Veterans Exploring
- 6mo agoHELPHelus Pharma to Participate at the 29th Annual Milken Institute Global ConferenceGlobeNewswireEric So, Interim CEO, to appear on panel entitled "The Next Wave of Health Innovation," on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a
- 6mo agoHELPHelus Pharma Partners with TARA Mind to Advance Veteran Mental HealthGlobeNewswireCollaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK
- 6mo agoHELPHelus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen BrannanGlobeNewswireAddition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026 (GLOBE NEWSWIRE) --
- 6mo agoATAICMPSHELPDFTXHow Trump's psychedelics executive order could unlock stalled cannabis reformCNBCThe White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine.
- 6mo agoHELPHelus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health ConditionsGlobeNewswireNEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic
- 6mo agoHELPHelus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive OfficerGlobeNewswireThis news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on
- 6mo agoHELPHelus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical AffairsGlobeNewswireDr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026
- 8mo agoHELPCMPSATAIDFTX+1CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsPR NewswireThe central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials...
- 8mo agoHELPACHCJNJBWAY+1Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar ExpansionPR NewswireMarket News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news...
- 8mo agoHELPHelus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety DisorderGlobeNewswireStatistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale ("HAM-A") of ~10 points on top of Standard of Care ("SoC") at 6 weeksDurable effects sustained through at
- 8mo agoHELPATAIDFTXGHRS+1Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsPR NewswireEquity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant...
- 8mo agoHELPCMPSRLMDANRO+1Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersPR NewswireUSA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that ...
- 8mo agoHELPTAKCMPSPFE+1Next-Generation Psychiatric Therapies Target Massive $40B+ Market OpportunityPR NewswireMental health disorders—including depression, anxiety, PTSD, and bipolar disorder—continue to represent one of the largest and fastest-growing areas...